Key statistics
On Friday, C4 Therapeutics Inc (CCCC:NSQ) closed at 5.38, 407.55% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.48 |
---|---|
High | 5.48 |
Low | 5.18 |
Bid | 5.30 |
Offer | 5.38 |
Previous close | 5.34 |
Average volume | 773.29k |
---|---|
Shares outstanding | 69.34m |
Free float | 61.26m |
P/E (TTM) | -- |
Market cap | 373.04m USD |
EPS (TTM) | -1.90 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 21:00 BST.
More ▼
Announcements
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
- C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
- C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
- C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
- C4 Therapeutics to Participate in Upcoming September Investor Conferences
- C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
- C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
- C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
More ▼